An interim analysis of a single arm, open-label, multicenter phase II study of capecitabine plus oxaliplatin (XELOX) as the perioperative treatment of patients with potentially resectable liver-only metastases from colorectal cancer (ML22298; NCT00997685)
机构：[1]Guangdong General Hospital, GI Surgery,Guangzhou City, China外科科室广东省人民医院[2]Guangzhou South Hospital, GI Surgery,Guangzhou City, China[3]The Second Affiliated Hospital of Zhong ShanUniversity, GI Surgery, Guangzhou City, China[4]Beijing Cancer Hospital,GI Surgery, Beijing City, China[5]The First Affiliated Hospital of KunmingMedical University, GI Surgery, Kunming City, China昆明医科大学附属第一医院[6]Jiangsu CancerHospital, GI Surgery, Nanjing City, China[7]The First Affiliated Hospitalof Zhejiang University, GI Surgery, Hangzhou City, China外科系统胃肠外科浙江大学医学院附属第一医院[8]ZhejiangCancer Hospital, GI Surgery, Hangzhou City, China浙江省肿瘤医院[9]Anhui ProvinceHospital, GI Surgery, Hefei City, China[10]The Affiliated Cancer Hospitalof Harbin Medical University, GI Surgery, Harbin City, China
第一作者机构：[1]Guangdong General Hospital, GI Surgery,Guangzhou City, China
推荐引用方式(GB/T 7714)：
Li F.,Li G.,Chu Z.,et al.An interim analysis of a single arm, open-label, multicenter phase II study of capecitabine plus oxaliplatin (XELOX) as the perioperative treatment of patients with potentially resectable liver-only metastases from colorectal cancer (ML22298; NCT00997685)[J].EUROPEAN JOURNAL OF CANCER.2013,49:S539-S539.
APA：
Li, F.,Li, G.,Chu, Z.,Hao, C.,Chen, M....&Wang, X..(2013).An interim analysis of a single arm, open-label, multicenter phase II study of capecitabine plus oxaliplatin (XELOX) as the perioperative treatment of patients with potentially resectable liver-only metastases from colorectal cancer (ML22298; NCT00997685).EUROPEAN JOURNAL OF CANCER,49,
MLA：
Li, F.,et al."An interim analysis of a single arm, open-label, multicenter phase II study of capecitabine plus oxaliplatin (XELOX) as the perioperative treatment of patients with potentially resectable liver-only metastases from colorectal cancer (ML22298; NCT00997685)".EUROPEAN JOURNAL OF CANCER 49.(2013):S539-S539
医学